M&R Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

M&R Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$148K	Buy	1,501 +301	+25%	+$29.6K	0.03%	157
2024 Q2	$111K	Hold	1,200	–	–	0.03%	169
2024 Q1	$114K	Hold	1,200	–	–	0.03%	169
2023 Q4	$107K	Hold	1,200	–	–	0.03%	191
2023 Q3	$87.6K	Hold	1,200	–	–	0.02%	196
2023 Q2	$99.8K	Hold	1,200	–	–	0.03%	187
2023 Q1	$91.5K	Hold	1,200	–	–	0.03%	192
2022 Q4	$99.6K	Hold	1,200	–	–	0.03%	188
2022 Q3	$95K	Hold	1,200	–	–	0.03%	190
2022 Q2	$89K	Sell	1,200 -500	-29%	-$37.5K	0.02%	196
2022 Q1	$152K	Hold	1,700	–	–	0.03%	165
2021 Q4	$190K	Hold	1,700	–	–	0.04%	157
2021 Q3	$213K	Hold	1,700	–	–	0.05%	145
2021 Q2	$230K	Hold	1,700	–	–	0.05%	144
2021 Q1	$230K	Sell	1,700 -15,930	-90%	-$2.39M	0.06%	134
2020 Q4	$2.48M	Sell	17,630 -435	-2%	-$55.7K	0.56%	39
2020 Q3	$2.01M	Sell	18,065 -950	-5%	-$107K	0.5%	44
2020 Q2	$2.13M	Buy	19,015 +13,460	+242%	+$1.33M	0.57%	41
2020 Q1	$430K	Hold	5,555	–	–	0.13%	110
2019 Q4	$528K	Hold	5,555	–	–	0.12%	120
2019 Q3	$423K	Hold	5,555	–	–	0.1%	133
2019 Q2	$487K	Sell	5,555 -450	-7%	-$38.4K	0.11%	125
2019 Q1	$523K	Buy	6,005 +1,560	+35%	+$133K	0.12%	121
2018 Q4	$318K	Sell	4,445 -5,745	-56%	-$463K	0.08%	141
2018 Q3	$976K	Buy	10,190 +185	+2%	+$17.9K	0.21%	91
2018 Q2	$952K	Buy	10,005 +1,200	+14%	+$110K	0.22%	91
2018 Q1	$772K	Buy	8,805 +90	+1%	+$8.22K	0.18%	101
2017 Q4	$739K	Buy	8,715 +1,025	+13%	+$85.9K	0.17%	100
2017 Q3	$665K	Hold	7,690	–	–	0.16%	104
2017 Q2	$582K	Hold	7,690	–	–	0.14%	109
2017 Q1	$533K	Buy	7,690 +550	+8%	+$36.9K	0.13%	115
2016 Q4	$422K	Buy	+7,140	New	+$441K	0.11%	132

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

M&R Capital Management's XBI Position: Q3 2024 in Review

M&R Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 25% in Q3 2024, buying an estimated $29.6K and bringing the position to 1,501 shares worth $148K. The position accounts for 0.03% of the portfolio, ranked #157.

M&R Capital Management first reported a position in XBI in Q4 2016 and has held it in 32 quarters since. The position peaked at $2.48M in Q4 2020. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

M&R Capital Management held 1,501 shares of State Street SPDR S&P Biotech ETF worth $148K as of Q3 2024.
M&R Capital Management bought 301 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $29.6K.
State Street SPDR S&P Biotech ETF made up 0.03% of M&R Capital Management's portfolio in Q3 2024, its #157 holding.
M&R Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 32 quarters since.
M&R Capital Management's State Street SPDR S&P Biotech ETF position peaked at $2.48M in Q4 2020.
769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on M&R Capital Management's 13F filing for Q3 2024, filed 2 Oct 2024.